KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Fulgent Genetics (FLGT) Equity Ratio (2016 - 2025)

Fulgent Genetics (FLGT) has disclosed Equity Ratio for 11 consecutive years, with 0.91 as the latest value for Q4 2025.

  • Quarterly Equity Ratio fell 1.47% to 0.91 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.91 through Dec 2025, down 1.47% year-over-year, with the annual reading at 0.91 for FY2025, 1.47% down from the prior year.
  • Equity Ratio hit 0.91 in Q4 2025 for Fulgent Genetics, down from 0.92 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.98 in Q4 2022 to a low of 0.8 in Q1 2021.
  • Historically, Equity Ratio has averaged 0.91 across 5 years, with a median of 0.92 in 2023.
  • Biggest YoY gain for Equity Ratio was 14.69% in 2021; the steepest drop was 11.93% in 2021.
  • Year by year, Equity Ratio stood at 0.91 in 2021, then increased by 7.73% to 0.98 in 2022, then fell by 6.6% to 0.92 in 2023, then rose by 0.89% to 0.93 in 2024, then dropped by 1.47% to 0.91 in 2025.
  • Business Quant data shows Equity Ratio for FLGT at 0.91 in Q4 2025, 0.92 in Q3 2025, and 0.93 in Q2 2025.